Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Florida: - AdventHealth Altamonte — Altamonte Springs, Florida
- AdventHealth Celebration — Celebration, Florida
- Holy Cross Hospital — Fort Lauderdale, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital — Hollywood, Florida
Phase 3 Recruiting Academic/Other
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Florida: - UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Springs — Coral Springs, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Florida: - Florida Cancer Specialists — Bonita Springs, Florida
- Florida Cancer Specialists — Bradenton, Florida
- Comprehensive Hematology Oncology — Brandon, Florida
- Florida Cancer Specialists — Cape Coral, Florida
- BRCR Global - Coral Springs — Coral Springs, Florida
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic color…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221357
Sites in Florida: - Florida Cancer Specialists - East — Cape Coral, Florida
- Florida Cancer Specialists - North — St. Petersburg, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 3 Recruiting Industry
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevaci…
Sponsor: Amgen
NCT ID: NCT06252649
Sites in Florida: - Cancer Specialists of North Florida - Southpoint — Jacksonville, Florida
- D and H Cancer Research Center — Margate, Florida
- Mid Florida Hematology and Oncology Centers PA — Orange City, Florida
- Boca Raton Clinical Research Medical Center Inc — Plantation, Florida
Phase 3 Recruiting Industry
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo. The questions to b…
Sponsor: Rapamycin Holdings Inc.
NCT ID: NCT06950385
Sites in Florida: - Digestive & Liver Center of Florida — Orlando, Florida
- Cleveland Clinic Florida — Weston, Florida
Phase 3 Recruiting Industry
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
Sponsor: Surgimab
NCT ID: NCT03659448
Sites in Florida: - Cleveland Clinic Florida — Weston, Florida
Phase 1, Phase 2 Recruiting Industry
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current sub…
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06445062
Sites in Florida: - Mayo Clinic Cancer Center — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Florida: - Mayo Clinic — Jacksonville, Florida
- Florida Cancer Specialists — Lake Mary, Florida
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Florida: - Helios CR Inc — Lakeland, Florida
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Phase 2 Recruiting Industry
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extensio…
Sponsor: Dogwood Therapeutics Inc.
NCT ID: NCT06848348
Sites in Florida: - Central Recruiting Site — Jacksonville, Florida
- Central Recruiting Site — Jacksonville, Florida
- Central Recruiting Site — Lakeland, Florida
- Central Recruiting Site — Orlando, Florida
- Central Recruiting Site — Port Charlotte, Florida
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Florida: - Life Clinical Trials — Coral Springs, Florida
- Bioresearch Partners — Hialeah, Florida
- D&H Cancer Research Center — Margate, Florida
- Mt. Sinai Cancer Center — Miami Beach, Florida
- BRCR Global — Tamarac, Florida
Phase 2 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess change in disease activity when telisotuzumab adizutecan is given alone compared to standard of care (SOC) given al…
Sponsor: AbbVie
NCT ID: NCT07023289
Sites in Florida: - Mayo Clinic Hospital Jacksonville /ID# 274472 — Jacksonville, Florida
- Moffitt Cancer Center /ID# 274372 — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Florida: - Florida Cancer Specialists — Sarasota, Florida
- Moffitt Cancer Center and Research Institute — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT05379985
Sites in Florida: - Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Florida: - AdventHealth Celebration — Celebration, Florida
- University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, two-part trial in participants with FAP.
Sponsor: Recursion Pharmaceuticals Inc.
NCT ID: NCT05552755
Sites in Florida: - GI Pros — Naples, Florida
- Digestive and Liver Center of Florida — Orlando, Florida
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Florida: - Mayo Clinic — Jacksonville, Florida
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesoth…
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06051695
Sites in Florida: - Mayo Clinic — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Florida: - University of Miami — Miami, Florida
- Biogenix — Miami, Florida
Phase 2 Recruiting Industry
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…
Sponsor: Bayer
NCT ID: NCT06760819
Sites in Florida: - Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus — Fort Myers, Florida
Phase 1, Phase 2 Recruiting Industry
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC)…
Sponsor: A2 Biotherapeutics Inc.
NCT ID: NCT06682793
Sites in Florida: - Mayo Clinic — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
Phase 2 Recruiting Network
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after the…
Sponsor: NSABP Foundation Inc
NCT ID: NCT07058012
Sites in Florida: - University of Florida — Gainesville, Florida
Phase 2 Recruiting Industry
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer
Sponsor: Criterium, Inc.
NCT ID: NCT06992258
Sites in Florida: - Mount Sinai Cancer Research Program — Miami Beach, Florida
- Orlando Health Cancer Institute — Orlando, Florida
Phase 1, Phase 2 Recruiting Industry
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
Sponsor: Apollo Therapeutics Ltd
NCT ID: NCT06399757
Sites in Florida: - Florida Cancer Specialists & Research Institute — Sarasota, Florida